Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 51

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 51
---
 of November14, 2025, the Company currently has outstanding: (i) 20,802,671shares of Common Stock, (ii) 1,429shares of Series A Preferred Stock with a conversion value of approximately $1.4 million, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a current effective conversion price of $0.05 per share; (iii) no shares of Series B Preferred Stock; (iv) 7shares of Series C Preferred Stock with a conversion value of $7,000, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a conversion price of $0.05 per share; (v) Series A Warrants to purchase 306shares of Common Stock at an exercise price of $2,780.00 per share; (vi) Series C Warrants to purchase 4,088shares of Common Stock at an exercise price of $0.80 per share; (vii) December 2024 and January 2025 Common Warrants to purchase an aggregate of 12,396shares of Common Stock at an exercise price ranging from $112.20 to $116.40 per share, (viii) February 2025 Common Warrants to purchase an aggregate of 127,551shares of Common Stock at an exercise price of $39.20 per share, (ix) February 2025 Pre -FundedWarrants to purchase an aggregate of 10,787shares of Common Stock at an exercise price of $0.002 per share, (x) Public Warrants and Private Placement Warrants to purchase an aggregate of 4,596shares of Common Stock at an exercise price of $23,000.00 per share, (xi) 5,368shares of Series D Preferred Stock with a conversion value of approximately $5.4million, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a current effective conversion price of $0.05 per share and (xii) 3,816shares of Series E Preferred Stock with a conversion value of approximately $3.8million, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a current effective conversion price of $4.1625 per share. Preferred Stock The Board is authorized to issue “blank check” Preferred Stock, which may be issued in one or more series upon the authorization of the Board. The Board is authorized to fix the designations